Activated inflammatory cells participate in thrombus size through tissue factor and plasminogen activator inhibitor-1 in acute coronary syndrome: Immunohistochemical analysis

Sakai, Tetsuo; Inoue, Shigeaki; Takei, Masatoshi; Ogawa, Genyo; Hamazaki, Yoko; Ota, Hidekazu; Koboyashi, Youichi

doi:10.1016/j.thromres.2011.02.001

Cited by 16 publications

(14 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Moreover, increased PAI-1 expression has been reported to potentially comprise a considerable portion of thrombus enlargement. 2 In our results, PAI-1 was more sensitive in determining acute coronary thrombus than d-dimer. The levels of PGM activity and PAI-1 were high in the AMI group.…”

Section: Clinical Importance Of Serum Pgm Activitysupporting

confidence: 52%

See 1 more Smart Citation

Phosphoglucomutase Activity as a Novel Biomarker in Patients With Acute Myocardial Infarction

Nishinari

Aoyama

Ogawa

et al. 2012

Circ J

View full text Add to dashboard Cite

Background: Phosphoglucomutase (PGM), a key enzyme in cellular glucose utilization and energy homeostasis, has been reported to show a relationship with oxidative stress. However, the clinical importance of PGM activity has not been investigated in patients with ischemic heart disease (IHD). The aim of the present pilot study was to clarify whether PGM activity has potential as a cardiovascular risk predictor in patients with IHD. Methods and Results:The levels of serum PGM activity in 237 patients with IHD (63 patients with acute myocardial infarction (AMI) and 174 patients with stable effort angina pectoris (EAP)) were evaluated. PGM activity was compared with levels of various myocardial, thrombosis, and inflammatory biomarkers on admission. PGM activity in the AMI group was significantly increased relative to that in the EAP group on admission (AMI, 55.5 μmol · min -1 · L -1 (U/L); EAP, 14.4 U/L (P<0.001)), and was observed to increase in parallel with well-established myocardial markers (P<0.001). Moreover, PGM activity and the lipid, thrombosis, and inflammatory biomarkers in the AMI group were higher than those in the EAP group.Conclusions: PGM activity increased with levels of myocardial, thrombosis, and inflammatory biomarkers in patients with AMI, and might be useful in diagnostic applications during the acute phase in patients with AMI. (Circ J 2012; 76: 2197 - 2203)

show abstract

Section: Clinical Importance Of Serum Pgm Activitysupporting

confidence: 52%

“…A total of 5 human serum samples were stored at 4°C, -20°C, and -70°C. We measured PGM activity after varying periods of storage (1,2,3,5,14, and 30 days) following serum sampling. The PGM activity at -20°C and -70°C was stable for up to 30 days but declined between days 5 and 14 at 4°C.…”

Section: Determination Of a Normal Level Of Pgm Activitymentioning

confidence: 99%

Phosphoglucomutase Activity as a Novel Biomarker in Patients With Acute Myocardial Infarction

Nishinari

Aoyama

Ogawa

et al. 2012

Circ J

View full text Add to dashboard Cite

show abstract

“…At the time of plaque disruption, locally released tissue factor-positive and leukocyte-derived MPs play an important role in fibrin-rich thrombus formation [35][36][37][38][39][40][41][42] . Moreover, activated inflammatory cells, such as neutrophils, macrophages and eosinophils, contribute to the growth of a thrombus 17,89,90) . Our study also demonstrated that erythrocyte-rich thrombi often contain more inflammatory cells, such as MPO-positive neutrophils, thus leading to increased plasma MPO levels, which reflects a high thrombus burden 78,84) .…”

Section: )mentioning

confidence: 99%

Thrombus Aspiration Therapy and Coronary Thrombus Components in Patients with Acute ST-Elevation Myocardial Infarction

Yunoki

Naruko

Sugioka

et al. 2013

JAT

View full text Add to dashboard Cite

Inflammation and oxidative stress play key roles in atherosclerotic plaque instability, and plaque rupture/erosion and subsequent thrombus formation constitute the principal mechanisms of total vessel occlusion and acute ST-elevation myocardial infarction (STEMI). Plaque disruption triggers the formation of initial platelet aggregates that grow in association with an increase in fibrin formation, leading to persistent coronary flow obstruction and blood coagulation. The fibrin network may trap large numbers of erythrocytes and inflammatory cells to form an erythrocyte-rich thrombus. In fact, previous clinical studies have shown that not only platelet-rich white thrombi, but also erythrocyte-rich red thrombi can be visualized using angioscopy in patients with acute coronary syndrome. Recently, the development of thrombus aspiration and distal protection devices has significantly improved the clinical outcomes of percutaneous intervention in STEMI patients and has enabled the evaluation of antemortem coronary artery thrombi. This is important because previous autopsy studies were unable to differentiate coronary thrombi responsible for myocardial ischemia from postmortem clots. Using frozen samples of aspirated thrombi and specific monoclonal antibodies, we investigated the cellular components of thrombi (platelets, erythrocytes, fibrin and inflammatory cells, such as myeloperoxidase-positive cells) and pathologically evaluated the relationships between erythrocyterich thrombi and inflammation, oxidative stress and clinical outcomes in STEMI patients. Therefore, this review article focuses on the efficacy of thrombus aspiration therapy and the components of aspirated intracoronary thrombi in STEMI patients and presents the results of recent studies regarding the relationship between the composition of aspirated intracoronary thrombi and clinical outcomes.

show abstract

“…The elevated PAI-1 level has been reported to be associated with glomerular disease, 3 DN, 4 retinopathy 5 and coronary artery disease. 6 In vivo, the plasma level of PAI-1 has been related to a common single base-pair guanine insertion/deletion polymorphism (4G/5G) within the promoter region of the PAI-1 gene at the nucleotide position (-675). 7 Several studies have reported contradictory results on the importance of PAI-1 4G/5G promoter polymorphism as a genetic risk marker in DN.…”

Section: Introductionmentioning

confidence: 99%

Association of plasminogen activator inhibitor-1 gene polymorphism and type 2 diabetic nephropathy

Liu

Sun

2015

Renal Failure

View full text Add to dashboard Cite

Background: We investigated the relationship between plasminogen activator inhibitor-1 (PAI-1) 4G/5G insertion/deletion polymorphism and prevalence of diabetic nephropathy (DN) in Chinese patients. Methods: A total of 107 patients with type 2 diabetes were randomly recruited in the study, and 102 healthy subjects were selected as Control. Patients were divided into three groups according to their urinary albumin-creatinine ratio (UACR). Group A (n ¼ 44), had patients without DN (serum creatinine 5106 mmol/L and UACR 530 mg/mg); Group B (n ¼ 30), had patients with micro-albuminuria (UACR 30-299 mg/mg), and Group C (n ¼ 33), had patients with macro-albuminuria (UACR !300 mg/mg and creatinine5200 mmol/L). Plasma level of PAI-1 was measured by ELISA. PAI-1 polymorphism was determined by a polymerase chain reaction (PCR) method and DNA sequencing. Results: (1) The plasma PAI-1 levels of group A (60.39 ± 17.01 ng/L), group B (68.76 ± 17.81 ng/L) and group C and (68.63 ± 18.30 ng/L) are higher than that of controls (46.26 ± 26.04 ng/L); (2) Patients with genotype 4G/4G tended to exhibit higher PAI-1 level; (3) The distribution frequency of genotype 4G/4G in group C was significantly higher than in group A (42.4% vs. 28.7%, p50.05) and (4) In type 2 diabetic patients, the occurrence of diabetes nephropathy in genotype 4G/4G, 4G/5G and 5G/5G is 35.0%, 30.2% and 21.4%, respectively. Conclusions: (1) Plasma PAI-1 level was elevated in Type 2 diabetic patients; (2) The level of plasma PAI-1 is closely related to PAI-1 gene 4G/5G polymorphism and (3) PAI-1 4G/5G polymorphism is associated with the development and progression of predominant proteinuria diabetes nephropathy.

show abstract

Activated inflammatory cells participate in thrombus size through tissue factor and plasminogen activator inhibitor-1 in acute coronary syndrome: Immunohistochemical analysis

Cited by 16 publications

References 37 publications

Phosphoglucomutase Activity as a Novel Biomarker in Patients With Acute Myocardial Infarction

Phosphoglucomutase Activity as a Novel Biomarker in Patients With Acute Myocardial Infarction

Thrombus Aspiration Therapy and Coronary Thrombus Components in Patients with Acute ST-Elevation Myocardial Infarction

Association of plasminogen activator inhibitor-1 gene polymorphism and type 2 diabetic nephropathy

Contact Info

Product

Resources

About